Related Experiment Video
Updated: Dec 5, 2025
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia
Francesco Salton1, Paola Confalonieri1, G Umberto Meduri2
1Department of Pulmonology, University Hospital of Cattinara, Trieste, Italy.
Background:
In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality.
Methods:
We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels.
Results:
Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24-0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12-0.73) and more days off invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the 2 groups (P = .84).
Conclusion:
In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. Clinical trial registration. ClinicalTrials.gov NCT04323592.
Insights
Early prolonged methylprednisolone (MP) treatment for severe COVID-19 pneumonia significantly reduced the need for intensive care unit (ICU) admission and mechanical ventilation (MV). This approach also decreased mortality by 71% and improved ventilator-free days, demonstrating safety and efficacy.
Area of Science:
- Critical Care Medicine
- Pulmonology
- Infectious Diseases
Background:
- Hospitalized patients with COVID-19 pneumonia face risks of acute respiratory failure, requiring invasive mechanical ventilation (MV), associated with high morbidity and mortality.
- Severe systemic inflammation is implicated as a key mechanism driving disease progression in COVID-19 pneumonia.
- Early intervention with prolonged methylprednisolone (MP) treatment is hypothesized to mitigate inflammation, accelerate recovery, and reduce critical care needs.
Purpose of the Study:
- To investigate the association between prolonged, low-dose methylprednisolone (MP) treatment and critical care outcomes in severe COVID-19 pneumonia.
- To evaluate the impact of MP treatment on the composite endpoint of ICU referral, intubation, or death within 28 days.
- To assess secondary outcomes including invasive MV-free days and C-reactive protein (CRP) level changes.
Main Methods:
- A multicenter observational study was conducted involving patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units.
- The study compared outcomes between patients receiving prolonged, low-dose MP treatment (n=83) and a control group (n=90).
- The primary endpoint was a composite of ICU referral, intubation, or death within 28 days; secondary outcomes included MV-free days and CRP levels.
Main Results:
- The composite primary endpoint occurred in 19% of the MP group versus 40% of the control group (aHR, 0.41).
- Fewer deaths were observed in the MP group (6% vs. 21%; aHR, 0.29), with significantly more invasive MV-free days (24.0 vs. 17.5).
- MP treatment was associated with rapid improvements in oxygenation (PaO2:FiO2) and CRP levels, with similar complication rates between groups.
Conclusions:
- Early, prolonged methylprednisolone (MP) administration in severe COVID-19 pneumonia is linked to a substantial reduction in mortality hazard (71%) and decreased ventilator dependence.
- The treatment demonstrated safety, with no adverse impact on viral clearance, and was associated with rapid clinical improvements.
- Findings are supported by subsequent validation from the RECOVERY trial, confirming the benefits of MP in this patient population.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:14Myocarditis III: Medical Management
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation